Genmab A/S (GMAB) is one of the most profitable biotech stocks to buy in 2025

From Yahoo Finance: 2025-04-02 09:47:00

The biotech industry is booming, with Genmab A/S (NASDAQ:GMAB) standing out among the most profitable biotech stocks to buy. Market growth is fueled by AI-driven drug discovery and innovative therapies, as the global biotech market is expected to reach $546.0 billion by 2025.

The Federal Reserve’s interest rate policies play a significant role in the biotech sector’s growth, with lower rates freeing up investment money for R&D and drug development. Genetic engineering, AI-driven drug discovery, and RNA therapeutics are transforming the industry, with CRISPR-based therapies and mRNA vaccines leading the way.

Genmab A/S (NASDAQ:GMAB) is a key player in the biotech sector, with groundbreaking antibody-based cancer therapies in its portfolio. Marketed medications like EPKINLY and TIVDAK have shown strong sales growth, positioning the company as one of the most profitable biotech stocks in 2025.

Investor interest in biotech equities is on the rise, driven by innovative treatments and promising drugs like Imdelltra and zanzalintinib. Leading investment banks see biotech as an undervalued opportunity, with AI-powered drug discovery and gene editing driving industry expansion.

GMAB ranks 3rd on the list of most profitable biotech stocks, with a focus on AI stocks for higher returns. Marketed medicines like EPKINLY and TIVDAK are driving Genmab’s revenue growth, making it a standout player in the biotech sector’s profitability.

Read more: Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?